Bio-Rad Introduces The IH-500, A Fully Automated Random Access System For Blood Typing And Screening

HERCULES, CA--(Marketwired - August 03, 2015) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), today announced the launch of the IH-500, a fully automated random access system for blood typing and screening, providing small and medium-size transfusion medicine laboratories fast and reliable results in a 24/7 environment. The IH-500 system is available in Europe, Asia, Africa, Australia, and Latin America.

The IH-500 system can handle the entire range of Bio-Rad ID gel cards for ABO blood grouping, reverse testing, phenotype, Rh-subgroups, antibody screening, antibody identification, single antigen testing, direct AHG testing (DAT), and crossmatch. The system incorporates a 6-axis robot transport arm offering a high level of automation and minimizing user operations. The IH-500 system also offers enhanced safety checks, extended reagent storage, and dynamic sample work flow management that provides additional efficiencies.

The seamless integration of IH-500 with IH-Com (software for data management and results interpretation) and IH-Web (software for remote result management) significantly improves the workflow from small labs to large lab networks.

“We are pleased to introduce the IH-500 automated blood typing system, a new and advanced generation of technology that has the flexibility to offer a cost-effective solution for both small and mid-volume labs,” said John Hertia, Bio-Rad Executive Vice President, President, Clinical Diagnostics Group. “The system reduces user operations and provides many new efficiencies to our customers.”

Key Benefits of IH-500 System

• Can operate as stand-alone system or as a bench-top analyzer, offering a high level of flexibility towards customized solutions
• As part of the total system solution, the IH-500 can be connected with other Bio-Rad instruments to create one seamlessly integrated lab system
• Incorporates proven industrial technology to provide a robust and reliable system
• Offers patient safety through established ID gel card technology as well as photo quality/clear results

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 7,600 people worldwide and had revenues exceeding $2.1 billion in 2014. For more information, please visit www.bio-rad.com.